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Guest Editorial | The future of toxicity testing 
Toxicity testing and assessment sit on the cusp 
of a transformational change brought about by 
the rapid emergence of tools and capabilities 
in molecular biology and computational and 
informational sciences. This transformation 
has the potential to dramatically reshape the philosophy and approaches 
underlying toxicity testing and the assessment of human health risks 
associated with exposure to environmental contaminants.
Such a transformation is especially significant for agencies that 
are responsible for implementing congressionally mandated pro-
grams under which the risks of exposure to a wide variety of envi-
ronmental pollutants are assessed and regulated. Most often, such 
regulatory decisions have relied on toxicity testing data obtained 
nearly exclusively from experimental animal models. This approach, 
however, presents challenges in accommodating the need for more 
efficient and cost-effective means to screen and prioritize chemicals 
for testing and addressing increasingly complex issues such as life-
stage susceptibility and genetic variations in the human population, 
the risks of concurrent, cumulative exposure to multiple and diverse 
chemicals, and, fundamental to all, improved understanding of the 
mechanism through which toxicity occurs.
The U.S. Environmental Protection Agency (EPA) has recognized 
the potential application of emerging science to improve toxicity test-
ing and risk assessment (U.S. EPA 2002, 2004), notably by taking the 
lead in commissioning the National Research Council (NRC) in 2004 
to review existing strategies (NRC 2006) and develop a long-range 
vision for toxicity testing and risk assessment (NRC 2007). Beyond 
EPA, other federal programs have also recognized the need for this 
transformative shift, as reflected in the National Toxicology Program’s 
(NTP) A National Toxicology Program for the 21st Century: Roadmap 
for the Future (NTP 2004) and the Food and Drug Administration’s 
FDA’s Critical Path Initiative (FDA 2008). 
To build on the NRC document, the U.S. EPA established 
an internal, cross-agency workgroup that produced The U.S. 
Environmental Protection Agency’s Strategic Plan for Evaluating the 
Toxicity of Chemicals (U.S. EPA 2009) to provide a framework for 
EPA to comprehensively move forward to incorporate this new 
scientific paradigm into future toxicity testing and risk assessment 
practices. The strategy is centered on three interrelated issues: a) the 
use of toxicity pathways information in screening and prioritization 
of chemicals for further testing; b) the use of toxicity pathways infor-
mation in risk assessment; and c) organizational transition. The last 
element explicitly recognizes that regulatory offices within EPA will 
need to be actively involved in overseeing the significant transition to 
this new paradigm and the translation of the attendant data for regu-
latory application. 
Research to address the first issue will build on the efforts of 
EPA’s ToxCast program in identifying and developing simple, reli-
able screening models to predict chemical hazard (U.S. EPA 2008a). 
The second effort will seek to apply the toxicity pathways concept 
in a systems biology approach, to better delineate the molecular 
and cellular changes that perturb normal homeostatic mechanisms 
toward a given toxicity pathway or set of toxicity pathways. This 
information should reduce the uncertainty currently associated with 
dose–response models by increasing their biological plausibility.  
Recognizing the necessity and benefits of collaboration to 
achieve the NRC’s vision, EPA recently signed a Memorandum of 
Understanding with the NTP and the National Institutes of Health 
Chemical Genomics Center (U.S. EPA(2008b) to advance the high 
throughput screening and toxicity pathway profiling in risk assess-
ment. This “Tox21” consortium is now actively coordinating efforts 
to identify chemicals, pathways, screening assays, and informatic 
approaches to assess the effects of thousands of chemicals (Kavlock 
et al. 2009). The U.S. EPA is also working with the European 
Commission and the Organization for Economic Cooperation and 
Development to facilitate global collaborations. 
As recognized by the NRC (2007), the development and imple-
mentation of a transformational paradigm will require a major 
commitment to new funding to sustain an iterative and long-term 
process that changes institutional toxicity testing and risk assessment 
practices. Regulators, stakeholders, and the public must be confident 
that the new types of data can be used to effectively assess risk and 
ultimately protect public health. As such, education and transpar-
ent communication will be critical. Ultimately, the testing paradigm 
must be evaluated via a comprehensive development and review 
process, involving public comment, expert peer review, and harmo-
nization with other agencies and international organizations. EPA’s 
Strategic Plan for Evaluating the Toxicity of Chemicals (U.S. EPA 
2009) lays the framework upon which the development, implemen-
tation, acceptance, and application of this transformative paradigm 
can be built. 
The views expressed in this letter are those of the individual authors and 
do not necessarily reflect the views of the U.S. EPA.
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